Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.200
+0.180 (4.48%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or -15.46% compared to the previous year.
Employees
134
Change (1Y)
-25
Growth (1Y)
-15.46%
Revenue / Employee
n/a
Profits / Employee
-$472,763
Market Cap
157.60M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 134 | -25 | -15.46% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Immunic | 100 |
| Corbus Pharmaceuticals Holdings | 36 |
| Jyong Biotech | 27 |
| Spruce Biosciences | 22 |
| Unicycive Therapeutics | 22 |
| Outlook Therapeutics | 17 |
MOLN News
- 11 days ago - Clear Street transfers coverage on Molecular Partners, keeps Buy rating - TheFly
- 21 days ago - Molecular Partners Reports H1 2026 Results, Advances DLL3 Radiotherapy MP0712 - Nasdaq
- 21 days ago - Molecular Partners AG Slides: Q2 2026 - Filings
- 21 days ago - Molecular Partners AG Earnings release: Q2 2026 - Filings
- 21 days ago - Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study - GlobeNewsWire
- 2 months ago - Molecular Partners doses first patients in MP0317 combination study - TheFly
- 2 months ago - Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - GlobeNewsWire
- 2 months ago - Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics - GlobeNewsWire